Log in  First Connection?

Lysosomal Storage Diseases: Archives News of the month

Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys

 Published on 04/04/2025 |  Original article (Abstract)  | Revel-Vilk Shoshana et al. | Orphanet Journal of Rare Diseases 2024; 20(1): 145

Fabry disease and Gaucher disease are rare genetic lysosomal storage disorders characterized by defective degradation of glycosphingolipids due to enzymatic deficiencies in α–galactosidase A and β–glucocerebrosidase, respectively [1, 2]. Patients with Fabry disease suffer from...

Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease

 Published on 28/03/2025 |  Original article (Abstract)  | Lenders Malte et al. | Orphanet Journal of Rare Diseases 2025; 20(1): 79

Fabry disease (FD; OMIM #301500) is an X-linked inherited lysosomal storage disease due to deficient α-galactosidase A activity (AGAL/GLA) based on pathogenic mutations within the GLA gene. The resulting FD-specific symptoms and manifestations originate from systemic cellular lysosomal...

Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: a tool to score natural history data in rare disease cohorts

 Published on 21/03/2025 |  Original article (Abstract)  | Lewis Connor J. et al. | Orphanet Journal of Rare Diseases 2025; 20(1): 125

Rare diseases in the US are defined by a prevalence of fewer than 200,000 individuals [1, 2]. Although individually unusual, rare diseases cumulatively affect approximately 4% of the global population and represent millions of individuals [3, 4]. Clinical trials pose a particular challenge to the rare...

Late-onset Pompe disease mimicking oculopharyngeal muscular dystrophy

 Published on 14/03/2025 |  Original article (Abstract)  | Moiz Mikail et al. | Practical Neurology 2025; aop:10.1136/pn-2024-004506

No data are available. Not Applicable. https://doi.org/10.1136/pn-2024-004506...

Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice

 Published on 07/03/2025 |  Original article (Abstract)  | Renzo Mignani   et al. | Advances in Therapy 2025; 42(2): 597-635

Fabry disease (FD) is a rare, X-linked, lysosomal storage disorder that results from deficient α-galactosidase A (α-Gal A) activity caused by a variant of the α-galactosidase (GLA) gene, with a prevalence estimated at around 1 in 40,000-170,000 births [1,2,3]. FD presents...